Ivosidenib: A Review in Advanced Cholangiocarcinoma
Targeted Oncology · 2023
DOI: 10.1007/s11523-023-01002-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Targeted Oncology, 2023. Verfasst von James E Frampton. Beteiligte Einrichtung: Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Ivosidenib (Tibsovo®), a first-in-class, oral small molecule, potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), is approved in the EU and USA for the treatment of adults with pretreated, advanced, mIDH1 cholangiocarcinoma (CCA). It is presumed to exert its cytostatic effects in this setting by suppressing 2-hydroxyglutarate, an oncometabolite produced by mIDH1 that impairs cellular differentiation and promotes tumorigenesis. In the multinational phase 3 ClarIDHy study in patients with pretreated, advanced mIDH1 CCA, monotherapy with ivosidenib once daily significantly prolonged progression-free survival (PFS) and almost doubled the disease control rate compared with placebo. Moreover, it had a favourable effect on overall survival (OS), which was also significantly prolonged after correcting for a high rate of crossover from the placebo group (permitted by the trial protocol). Ivosidenib treatment preserved health-related quality of life (HRQOL) relating to physical function, pain and appetite loss/eating and was generally well tolerated, with the most common treatment-emergent adverse events being low-grade diarrhoea, nausea and fatigue. Thus, ivosidenib represents a novel and valuable targeted therapy for the subset of patients with pretreated, advanced CCA tumors harbouring mIDH1. Cholangiocarcinoma (CCA) is often diagnosed at an advanced stage when the prognosis is poor due to limited treatment options, including standard-of-care (palliative) chemotherapy. Around 40% of patients with CCA have a tumor that can be targeted for treatment due to the presence of a molecular abnormality implicated in tumor formation and/or maintenance. One such abnormality (present in ≈14% of patients with intrahepatic CCA), is a mutated form of the isocitrate dehydrogenase 1 (IDH1) enzyme (‘mutant IDH1’) that inappropriately catalyses the production of 2-hydroxyglutarate (2-HG), an oncometabolite that promotes tumorigenesis. Ivosidenib (Tibsovo®), a first-in-class, small molecule, oral inhibitor of mIDH1, exerts a cytostatic (stabilizing) effect on mIDH1 CCA tumors, presumably by suppressing the production of 2-HG. Compared with placebo, ivosidenib resulted in a statistically significant, near-doubling of progression-free survival and, similarly, a near doubling of the disease control rate in a pivotal study in patients with pretreated, advanced, mIDH1 CCA. Overall survival was also significantly improved after controlling for the high rate of crossover. Health-related quality of life was maintained and ivosidenib treatment was generally well tolerated. Ivosidenib represents a novel and valuable targeted therapy for patients with advanced mIDH1 CCA tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.
Zitieren
APA
Frampton, J. E. (2023). Ivosidenib: A Review in Advanced Cholangiocarcinoma. Targeted Oncology. https://doi.org/10.1007/s11523-023-01002-3
Vancouver
Frampton JE. Ivosidenib: A Review in Advanced Cholangiocarcinoma. Targeted Oncology. 2023. doi:10.1007/s11523-023-01002-3
BibTeX
@article{Frampton2023,
author = {Frampton, James E},
title = {Ivosidenib: A Review in Advanced Cholangiocarcinoma},
journal = {Targeted Oncology},
year = {2023},
doi = {10.1007/s11523-023-01002-3}
}
EUVIMED